[Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
BACKGROUND
The prevalence of chronic headaches in children and adolescents is up to 2 % resulting in the beginning of the later typical headache careers of adults. The therapy for chronic migraine with botulinum toxin is now established in adults. However, there is only limited experience in the use of botulinum toxin in paediatric patients.


METHODS
10 patients aged 13 - 17 years who suffered from chronic migraine according to the IHS criteria were injected at 31 specific injection points of the head and neck muscles with a total amount of 150 IE of botulinum toxin A (Botox®) according to the approved scheme. The number of headache days per month over the following 9 months was recorded and side effects were retrospectively determined.


RESULTS
The responder rate (that is reduction of headache days per month more than 50 %) was 7/10 at three months after the injection. On average the number of headache days per month was reduced from 19.2 days to a minimum of 10.1 days. After three to six months the number of headache days increased again in all responders. Slight local side effects such as redness or temporary pain were observed in all patients, but severe side effects such as infections, fever, ptosis or allergic reactions did not occur.


CONCLUSIONS
This small case series shows that the therapy for chronic migraine with botulinum toxin A can also be effective and safe in adolescents. As many adolescents still suffer from headaches later as adults a link between neuropaediatricians and neurologists is justifiable. An early botulinum toxin therapy followed by the transition of the adolescents would be helpful.
M K
MK
Bernhard
A
A
Bertsche
S
S
Syrbe
S
S
Weise
A
A
Merkenschlager
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D009462:Neurology; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010372:Pediatrics; D012189:Retrospective Studies; D000077236:Topiramate; D004561:Transcutaneous Electric Nerve Stimulation; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D009465:Neuromuscular Agents; D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose; D019274:Botulinum Toxins, Type A; D008790:Metoprolol